There have been numerous preclinical studies in rodent models assessing inhibitors of the CCL2-CCR2 axis using either small molecule CCL2 inhibitors or monoclonal antibodies, and most have demonstrated inhibition of tumor growth and/or decreased metastatic burden (120). This evidence concerns the gene CCR2 and neoplasm.